GILD Jan 2025 37.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:34PM EDT. Market open.
Loading interactive chart...
- Simply Wall St.
Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Gilead Sciences ( NASDAQ:GILD ) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q...
- Investor's Business Daily
Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
- Zacks
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
© 2024 Yahoo. All rights reserved.